Drug Profile
Research programme: JNK-1 inhibitors - Galapagos
Alternative Names: BF 67192; BF 67193; JNK-1 inhibitors research programme - BioFocusLatest Information Update: 13 Apr 2007
Price :
$50
*
At a glance
- Originator Galapagos NV
- Class
- Mechanism of Action Mitogen-activated protein kinase 8 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 13 Apr 2007 No development reported - Preclinical for Inflammation in United Kingdom (unspecified route)
- 04 Nov 2005 BioFocus has been acquired and merged into Galapagos NV
- 31 Dec 2003 BioFocus' JNK-1 inhibitors programme is available for licensing (http://www.biofocus.com)